文献速递淋巴瘤

利妥昔单抗联合甲氨蝶呤序贯利妥昔单抗联合阿糖胞苷治疗老年原发性中枢神经系统淋巴瘤

Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma.
PubMed 文献 · Br J Haematol · 2024-08-05

这项II期研究评估利妥昔单抗联合大剂量甲氨蝶呤诱导后序贯利妥昔单抗联合阿糖胞苷巩固方案,用于年龄≥60岁初诊原发性中枢神经系统淋巴瘤患者。共入组35例,中位年龄73岁。2年无进展生存率为58.7%,2年总生存率为77.9%,仅3例因毒性退出研究,无治疗相关死亡。

要点

  • 诱导治疗后完全缓解率和部分缓解率分别为56%和20%。
  • 巩固治疗后完全缓解率和部分缓解率分别为59%和9%。
  • 2年无进展生存率58.7%,2年总生存率77.9%,仅3例因毒性退出。

核心结论

  • 本研究可能提示,在年龄≥60岁的原发性中枢神经系统淋巴瘤患者中给予大剂量甲氨蝶呤联合阿糖胞苷具有可行性,并提示利妥昔单抗可能具有附加作用。

研究设计与样本

  • II期研究,评估利妥昔单抗联合大剂量甲氨蝶呤诱导后序贯利妥昔单抗联合阿糖胞苷巩固方案,用于年龄≥60岁初诊原发性中枢神经系统淋巴瘤患者。
  • 共入组35例患者,中位年龄73岁(范围:60-81)。
  • 主要终点为2年无进展生存率。
  • 诱导治疗为大剂量甲氨蝶呤联合利妥昔单抗,巩固治疗为两个周期的阿糖胞苷联合利妥昔单抗。

主要发现

  • 诱导治疗后,完全缓解率为56%,部分缓解率为20%。
  • 26例患者进入巩固治疗,巩固治疗后完全缓解率为59%,部分缓解率为9%。
  • 中位随访36.0个月后,2年无进展生存率为58.7%。
  • 2年总生存率为77.9%。
  • 仅3例患者因毒性退出研究,未报告治疗相关死亡。

临床怎么用

  • 原文结论未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The optimal treatment strategy for newly diagnosed primary central nervous system lymphoma (PCNSL) has yet to be established, especially in the elderly. In the current study, we conducted a phase II study to evaluate the efficacy and safety of rituximab plus high-dose MTX followed by rituximab plus cytarabine in patients aged ≥60 years newly diagnosed with PCNSL. Patients received an induction treatment of high-dose methotrexate plus rituximab followed by two cycles of a consolidation treatment of cytarabine plus rituximab. The primary end-point was a 2-year progression-free survival (PFS) rate. A total of 35 patients were recruited, and their median age was 73 (range: 60-81). After induction treatment, the complete and partial responses (PRs) were 56% and 20% respectively. Twenty-six patients proceeded to the consolidation treatment; the complete and PRs were 59% and 9% respectively. After a median follow-up duration of 36.0 months, the 2-year PFS rate was 58.7%. Treatment was generally well-tolerated as only three patients were withdrawn from the study due to toxicity, and no treatment-related mortality was reported. The 2-year overall survival rate was 77.9%. The current study may suggest the feasibility of administering high-dose MTX plus cytarabine in PCNSL patients aged ≥60 years and the potential role of additive rituximab.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Yi JH, Kim SJ, Yang DH, et al. Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma. Br J Haematol. 2024. PMID: 39104032. doi:10.1111/bjh.19659

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。